
Medicine and Health
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
J. F. E. Mann, P. Rossing, et al.
This study by Johannes F. E. Mann and colleagues reveals how semaglutide can significantly reduce kidney failure risks in type 2 diabetes and chronic kidney disease, highlighting its benefits whether used with SGLT2 inhibitors or not. Discover the implications of these findings for treatment strategies in diabetes care.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.